Special Issue "Bispecific Antibodies for Dual Targeting Strategies"
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (28 February 2013)
Prof. Dr. Roland Kontermann (Website)
Institut für Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 31, D-70569 Stuttgart, Germany
Interests: bifunctional antibody fusion proteins; half-life extension strategies; targeted nanoparticulate drug delivery systems
Bispecific antibodies are emerging as novel approach for dual targeting strategies combining two different antigen-binding sites within one molecules. Bispecific antibodies allow to improve binding, selectivity and efficacy, e.g. by simultaneously inhibiting two receptors or cytokines. A multitude of bispecific antibody formats have been developed in the recent years and novel applications have been established, including the dual retargeting of toxins, cytokines and growth factors with bispecific antibody fusion proteins but also dual retargeting of effector cells of the immune system with trispecific antibodies. Furthermore, dual targeting is applied to nanoparticles for delivery of drugs to target cells. Main indications include tumor therapy and the treatment of inflammatory diseases, but new areas for application of dual targeting strategies are also emerging, e.g. in diagnosis and imaging. Recent studies have already shown that bispecific antibodies show similar or even improved efficacy compared with combination therapy with two antibodies, thus offer an alternative to the parallel development, production and approval of two monoclonal antibodies.
This special issue of Antibodies addresses the growing interest in dual targeting strategies using bispecific antibodies and I kindly invite you to submit your novel results to this special issue. Welcome are manuscripts describing the application of bispecific antibodies for dual targeting strategies using in vitro and in vivo studies as well as manuscript dealing with novel bispecific antibody formats and fusion proteins suitable for dual targeting strategies.
Prof. Dr. Roland E. Kontermann
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- bispecific antibodies for dual targeting of tumor cells
- bispecific antibodies for dual neutralization of cytokines and growth factors
- bispecific antibodies for dual targeting for receptor activation
- bispecific antibodies for dual retargeting of cytokines and growth factors
- bispecific antibodies for dual retargeting of immune effector cells
- bispecific antibodies for dual retargeting of toxins
- antibodies for dual retargeting of nanoparticles and liposomes
- new bispecific antibody formats
- bispecific antibodies for tumor therapy
- bispecific antibodies for therapy of inflammatory diseases
- bispecific antibodies for therapy of infectious diseases
- bispecific antibodies for imaging and diagnosis
- bispecific antibodies for half-life extension